

# Robert S Kerbel

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5274582/robert-s-kerbel-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164  
papers

23,268  
citations

66  
h-index

152  
g-index

173  
ext. papers

25,206  
ext. citations

12.1  
avg, IF

7.39  
L-index

#	Paper	IF	Citations
164	Tumors resurrect an embryonic vascular program to escape immunity.. <i>Science Immunology</i> , <b>2022</b> , 7, eabm6388	18.6	388
163	Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e08253	12	2
162	Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Lancet, The</i> , <b>2021</b> , 398, 278-279	40	1
161	Metronomic chemotherapy offsets HIF $\alpha$ induction upon maximum-tolerated dose in metastatic cancers. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e11416	12	9
160	A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e12355	12	3
159	Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 29	7.8	9
158	Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. <i>Oncogene</i> , <b>2020</b> , 39, 187-203	9.2	19
157	Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity. <i>Angiogenesis</i> , <b>2019</b> , 22, 535-546	10.6	3
156	Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222580	3.7	4
155	Vessel co-option in cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 469-493	19.4	158
154	Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2019</b> , 38, 16	12.8	20
153	Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 196-206	8.7	17
152	Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion <b>2019</b> , 14, e0222580		
151	Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion <b>2019</b> , 14, e0222580		
150	Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion <b>2019</b> , 14, e0222580		
149	Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion <b>2019</b> , 14, e0222580		
148	Non-angiogenic tumours and their influence on cancer biology. <i>Nature Reviews Cancer</i> , <b>2018</b> , 18, 323-336	13	77

147	Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 869-882	6.1	14
146	Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. <i>Nature Reviews Clinical Oncology</i> , <b>2018</b> , 15, 310-324	19.4	234
145	Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 1602-1612	6.1	5
144	Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196892	3.7	5
143	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , <b>2018</b> , 21, 425-538	538	285
142	Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models. <i>Angiogenesis</i> , <b>2018</b> , 21, 793-804	10.6	2
141	Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases. <i>Scientific Reports</i> , <b>2018</b> , 8, 9013	4.9	20
140	The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease. <i>Cancer Letters</i> , <b>2017</b> , 400, 293-304	9.9	43
139	A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature. <i>Cancer Cell</i> , <b>2017</b> , 31, 469-471	24.3	7
138	Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. <i>Trends in Cancer</i> , <b>2017</b> , 3, 529-541	541.5	63
137	Development of Orthotopic and Spontaneous Metastatic Human Tumor Xenograft Models for Experimental Therapeutics. <i>Molecular and Translational Medicine</i> , <b>2017</b> , 161-182	0.4	
136	Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. <i>Journal of Pathology</i> , <b>2017</b> , 241, 362-374	9.4	119
135	Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy. <i>Cancer Research</i> , <b>2016</b> , 76, 5983-5993	10.1	36
134	Mouse Models of Advanced Spontaneous Metastasis for Experimental Therapeutics. <i>Methods and Principles in Medicinal Chemistry</i> , <b>2016</b> , 109-127	0.4	
133	Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. <i>Chinese Journal of Cancer</i> , <b>2016</b> , 35, 97		17
132	Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer. <i>Cancer Research</i> , <b>2016</b> , 76, 4493-503	10.1	43
131	Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 974-81	1	73
130	Antiangiogenic therapy in oncology: current status and future directions. <i>Lancet, The</i> , <b>2016</b> , 388, 518-29	40	507

129	Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note. <i>PLoS ONE</i> , <b>2016</b> , 11, e0158034	3.7	20
128	Therapy-activated stromal cells can dictate tumor fate. <i>Journal of Experimental Medicine</i> , <b>2016</b> , 213, 2831-2839	12.9	39
127	Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. <i>Scientific Reports</i> , <b>2016</b> , 6, 36694	4.9	13
126	Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 659-673	19.4	112
125	Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	105
124	Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. <i>Cancer Research</i> , <b>2016</b> , 76, 6988-7000	10.1	36
123	Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5488-98	12.9	23
122	Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. <i>Cancer Research</i> , <b>2015</b> , 75, 2510-9	10.1	50
121	Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 808-18	12.9	57
120	Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 282ra50	17.5	40
119	Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2. <i>EMBO Molecular Medicine</i> , <b>2015</b> , 7, 770-87	12	23
118	Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. <i>Oncologist</i> , <b>2015</b> , 20, 1351-2	5.7	13
117	Lessons from the first e cancer symposium on angiogenesis in gastric cancer. <i>Ecancermedicalscience</i> , <b>2015</b> , 9, 553	2.7	
116	Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 42396-410	3.3	33
115	Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 313-4	19.4	22
114	A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2015</b> , 21, 274-83	2.2	40
113	PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2138-47	12.9	56
112	Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. <i>Angiogenesis</i> , <b>2014</b> , 17, 661-73	10.6	16

111	Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis. <i>Angiogenesis</i> , <b>2014</b> , 17, 641-59	10.6	24
110	Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. <i>EMBO Molecular Medicine</i> , <b>2014</b> , 6, 1561-76	12	31
109	Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. <i>Leukemia Research</i> , <b>2014</b> , 38, 756-63	2.7	14
108	Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment. <i>Angiogenesis</i> , <b>2014</b> , 17, 129-46	10.6	17
107	Development and Evolution of the Concept of Metronomic Chemotherapy: A Personal Perspective <b>2014</b> , 3-21		2
106	Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. <i>Ecancermedalscience</i> , <b>2014</b> , 8, 463	2.7	25
105	Drug rechallenge and treatment beyond progression--implications for drug resistance. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 571-87	19.4	174
104	Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, E1465-73	5.6	30
103	Focused ultrasound delivers targeted immune cells to metastatic brain tumors. <i>Cancer Research</i> , <b>2013</b> , 73, 1892-9	10.1	137
102	Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastasis. <i>Breast</i> , <b>2013</b> , 22 Suppl 2, S57-65	3.6	35
101	Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. <i>Gut</i> , <b>2013</b> , 62, 259-71	19.2	89
100	Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. <i>Translational Oncology</i> , <b>2013</b> , 6, 511-9	4.9	29
99	A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. <i>Cancer Research</i> , <b>2013</b> , 73, 2743-8	10.1	75
98	Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2R(hull) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis. <i>PLoS ONE</i> , <b>2013</b> , 8, e71270	3.7	31
97	Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , <b>2012</b> , 17, 229-39	2.4	30
96	Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 673-88	14.4	85
95	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. <i>Angiogenesis</i> , <b>2012</b> , 15, 275-86	10.6	53
94	Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 680-9	6.1	34

93	Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 210-21	19.4	534
92	Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. <i>Neoplasia</i> , <b>2011</b> , 13, 40-8	6.4	51
91	G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. <i>Blood</i> , <b>2011</b> , 118, 3426-35	2.2	50
90	Mouse models of advanced spontaneous metastasis for experimental therapeutics. <i>Nature Reviews Cancer</i> , <b>2011</b> , 11, 135-41	31.3	289
89	Reappraising antiangiogenic therapy for breast cancer. <i>Breast</i> , <b>2011</b> , 20 Suppl 3, S56-60	3.6	54
88	Forty-year journey of angiogenesis translational research. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 114rv317.5	17.5	144
87	Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5656-67	12.9	64
86	Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. <i>Neoplasia</i> , <b>2011</b> , 13, 187-97	6.4	28
85	Peering into the aftermath: The inhospitable host?. <i>Nature Medicine</i> , <b>2010</b> , 16, 1084-5	50.5	19
84	Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 996-1006	6.1	92
83	Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. <i>MAbs</i> , <b>2010</b> , 2, 199-208	6.6	47
82	Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. <i>Neoplasia</i> , <b>2010</b> , 12, 928-40	6.4	57
81	Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. <i>Neoplasia</i> , <b>2010</b> , 12, 264-74	6.4	43
80	Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. <i>Recent Results in Cancer Research</i> , <b>2010</b> , 180, 165-83	1.5	26
79	Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy <b>2010</b> , 257-273		
78	Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action <b>2010</b> , 117-134		1
77	Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. <i>Cancer Research</i> , <b>2009</b> , 69, 7243-51	10.1	274
76	A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 14028-33	11.5	103

75	Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 2872-81	6.1	72
74	Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4867-74	12.9	30
73	Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6358-66	12.9	37
72	Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. <i>Cancer Research</i> , <b>2009</b> , 69, 7524-8	10.1	78
71	Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5020-5	12.9	231
70	Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. <i>Cancer Cell</i> , <b>2009</b> , 15, 3-5	24.3	37
69	Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. <i>Cancer Cell</i> , <b>2009</b> , 15, 232-9	24.3	1455
68	Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. <i>Breast</i> , <b>2009</b> , 18 Suppl 3, S41-7	3.6	30
67	Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. <i>Cancer Cell</i> , <b>2008</b> , 14, 263-73	24.3	375
66	Tumor Angiogenesis and the Cancer Stem Cell Model <b>2008</b> , 249-258		1
65	Tumor angiogenesis. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2039-49	59.2	1788
64	Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 3452-9	6.1	29
63	Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. <i>Cancer Research</i> , <b>2008</b> , 68, 4500-5	10.1	109
62	Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Disease <b>2008</b> , 63-80		
61	Taxanes Induce a Rapid Mobilization of Different Populations of Circulating Endothelial Progenitors by SDF-1 Modulation in Cancer Patients.. <i>Blood</i> , <b>2008</b> , 112, 1885-1885	2.2	
60	Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis. <i>Molecular Imaging</i> , <b>2007</b> , 6, 7290.2007.00024	3.7	85
59	Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. <i>Cancer Research and Treatment</i> , <b>2007</b> , 39, 150-9	5.2	40
58	Molecular and cellular biomarkers for angiogenesis in clinical oncology. <i>Drug Discovery Today</i> , <b>2007</b> , 12, 806-12	8.8	78



57	On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. <i>Cancer and Metastasis Reviews</i> , <b>2007</b> , 26, 737-47	9.6	39
56	Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. <i>Cancer Research</i> , <b>2007</b> , 67, 7055-8	10.1	103
55	Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. <i>Oncology Research and Treatment</i> , <b>2007</b> , 30, 606-8	2.8	20
54	Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. <i>Molecular Cancer Therapeutics</i> , <b>2007</b> , 6, 2280-9	6.1	40
53	Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. <i>Cancer Research</i> , <b>2007</b> , 67, 3560-4	10.1	330
52	Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1816-32	3 <sup>2</sup>	50
51	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 17069-74	11.5	331
50	Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. <i>Cancer Research</i> , <b>2006</b> , 66, 3386-91	10.1	197
49	Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 904-16	12.9	127
48	Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. <i>Cancer Research</i> , <b>2006</b> , 66, 3639-48	10.1	140
47	Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4331-8	12.9	63
46	High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5190-8	12.9	93
45	Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. <i>Science</i> , <b>2006</b> , 313, 1785-7	33.3	505
44	Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. <i>Science</i> , <b>2006</b> , 312, 1171-5	33.3	403
43	Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. <i>Blood</i> , <b>2006</b> , 108, 452-9	2.2	221
42	The multifaceted circulating endothelial cell in cancer: towards marker and target identification. <i>Nature Reviews Cancer</i> , <b>2006</b> , 6, 835-45	31.3	505
41	Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. <i>Blood</i> , <b>2005</b> , 106, 3058-61	2.2	224
40	Angiogenesis as a therapeutic target. <i>Nature</i> , <b>2005</b> , 438, 967-74	50.4	2127



39	Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. <i>Cancer Cell</i> , <b>2005</b> , 7, 101-11	24.3	315
38	Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. <i>Cancer Cell</i> , <b>2005</b> , 8, 269-71	24.3	57
37	Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1484-94	6.1	31
36	In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. <i>Cancer Research</i> , <b>2005</b> , 65, 5365-73	10.1	69
35	Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. <i>Cancer Research</i> , <b>2005</b> , 65, 7045-51	10.1	121
34	A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. <i>Cancer Research</i> , <b>2004</b> , 64, 3994-4000	10.1	119
33	Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. <i>Cancer Research</i> , <b>2004</b> , 64, 6616-25	10.1	150
32	The anti-angiogenic basis of metronomic chemotherapy. <i>Nature Reviews Cancer</i> , <b>2004</b> , 4, 423-36	31.3	1156
31	Antiangiogenic drugs and current strategies for the treatment of lung cancer. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 54-60	5.5	25
30	A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma. <i>Molecular Cancer Research</i> , <b>2004</b> , 2, 315-326	6.6	125
29	Some guidelines for building a successful career in cancer research. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, 111-4	4.6	2
28	Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. <i>European Journal of Pharmacology</i> , <b>2003</b> , 477, 17-21	5.3	5
27	Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. <i>Cancer</i> , <b>2003</b> , 98, 1643-8	6.4	139
26	Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived But They Can Be Improved. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, 133-138	4.6	121
25	Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. <i>Cancer Research</i> , <b>2003</b> , 63, 4342-6	10.1	333
24	Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, S134-9	4.6	173
23	Reply to "Limitations of combination anti-angiogenesis and chemotherapy" <i>Nature Reviews Cancer</i> , <b>2002</b> , 2, 804-804	31.3	
22	Clinical translation of angiogenesis inhibitors. <i>Nature Reviews Cancer</i> , <b>2002</b> , 2, 727-39	31.3	1299

21	A role for survivin in chemoresistance of endothelial cells mediated by VEGF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 4349-54	11.5	375
20	Effect of p53 status on tumor response to antiangiogenic therapy. <i>Science</i> , <b>2002</b> , 295, 1526-8	33.3	382
19	Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. <i>Cancer Research</i> , <b>2002</b> , 62, 2731-5	10.1	211
18	Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. <i>Cancer Research</i> , <b>2002</b> , 62, 6938-43	10.1	290
17	Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. <i>Cancer and Metastasis Reviews</i> , <b>2001</b> , 20, 79-86	9.6	191
16	Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. <i>Oncogene</i> , <b>2000</b> , 19, 395-402	9.2	46
15	Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. <i>Oncogene</i> , <b>2000</b> , 19, 4611-20	9.2	170
14	Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. <i>Journal of Clinical Investigation</i> , <b>2000</b> , 105, R15-24	15.9	884
13	Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. <i>Oncogene</i> , <b>1999</b> , 18, 1023-32	9.2	68
12	Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. <i>International Journal of Cancer</i> , <b>1999</b> , 81, 118-24	7.5	82
11	The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. <i>Angiogenesis</i> , <b>1998</b> , 2, 203-17	10.6	25
10	What is the optimal rodent model for anti-tumor drug testing?. <i>Cancer and Metastasis Reviews</i> , <b>1998</b> , 17, 301-4	9.6	44
9	Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. <i>International Journal of Cancer</i> , <b>1997</b> , 74, 464-9	7.5	137
8	Differential expression patterns of S100a2, S100a4 and S100a6 during progression of human malignant melanoma <b>1997</b> , 74, 464		6
7	Commentaries on tumor angiogenesis: an introduction. <i>Cancer and Metastasis Reviews</i> , <b>1996</b> , 15, 145-147	7.6	3
6	Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. <i>Nature Medicine</i> , <b>1996</b> , 2, 1204-10	50.5	275
5	Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. <i>Journal of Cellular Physiology</i> , <b>1994</b> , 159, 245-55	7	50
4	Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines. <i>International Journal of Cancer</i> , <b>1991</b> , 48, 557-61	7.5	10

3	Extensive multi-organ metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. <i>International Journal of Cancer</i> , <b>1991</b> , 49, 938-9	7.5	61
2	Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. <i>BioEssays</i> , <b>1991</b> , 13, 31-6	4.1	378
1	Metronomic Chemotherapy for Treatment of Metastatic Disease: From Preclinical Research to Clinical Trials573-586		1